预测局部晚期直肠癌术前同步放化疗敏感性的生物学指标

doi:10.3760/cma.j.cn371439-20220429-00110

摘要/Abstract

摘要：

局部晚期直肠癌术前同步放化疗后肿瘤降期明显,可提高保肛率及局部控制率,不良反应可耐受,但临床疗效个体差异大。近年来研究发现,环氧合酶-2、G蛋白偶联受体、P53结合蛋白1、纤维蛋白原/白蛋白比值、程序性细胞死亡因子4、肿瘤浸润淋巴细胞、微小RNA等生物学指标与局部晚期直肠癌新辅助治疗的敏感性相关,可预测术前同步放化疗的敏感性。

关键词: 直肠肿瘤, 化放疗, 敏感性与特异性

Abstract:

After the preoperative concurrent chemoradiotherapy for local advanced rectal cancer, the down-staging of tumor is obvious, the rate of anal preservation and the local control rate are improved, and the side reactions are acceptable, but the individual clinical efficacy varies greatly. Recent studies have found that cyclooxygenase-2, G protein coupled receptor, P53 binding protein 1, fibrinogen-to-albumin ratio, pro-grammed cell death factor 4, tumor infiltrating lymphocytes, microRNA are related to the sensitivity of neoadjuvant therapy for locally advanced rectal cancer, which can predict the sensitivity of preoperative concurrent chemoradiotherapy.

Key words: Rectal neoplasms, Chemoradiotherapy, Sensitivity and specificity

李志磊, 罗加林. 预测局部晚期直肠癌术前同步放化疗敏感性的生物学指标[J]. 国际肿瘤学杂志, 2022, 49(9): 564-567.

Li Zhilei, Luo Jialin. Biological indexes for predicting sensitivity of preoperative concurrent chemoradiotherapy for locally advanced rectal cancer[J]. Journal of International Oncology, 2022, 49(9): 564-567.

参考文献 30

[1]	Mendis S, To YH, Tie J. Biomarkers in locally advanced rectal cancer: a review[J]. Clin Colorectal Cancer, 2022, 21(1): 36-44. DOI: 10.1016/j.clcc.2021.11.002. doi: 10.1016/j.clcc.2021.11.002
[2]	Marin S, Pérez-Cordón L, Salvà F, et al. Cost-minimisation analysis of rectal cancer neoadjuvant chemoradiotherapy based on fluoropyrimidines (capecitabine versus 5-fluorouracil)[J]. Eur J Hosp Pharm, 2021, 28(Suppl 2): e13-e17. DOI: 10.1136/ejhpharm-2019-002156. doi: 10.1136/ejhpharm-2019-002156
[3]	Shinto E, Omata J, Sikina A, et al. Predictive immunohistochemical features for tumour response to chemoradiotherapy in rectal cancer[J]. BJS Open, 2020, 4(2): 301-309. DOI: 10.1002/bjs5.50251. doi: 10.1002/bjs5.50251 pmid: 32026629
[4]	刘英强, 陈淅涓, 韩广森, 等. 中低位局部进展期直肠癌新辅助同步放化疗敏感性与环氧化酶-2表达的关系[J]. 中华实验外科杂志, 2018, 35(8): 1548-1550. DOI: 10.3760/cma.j.issn.1001-9030.2018.08.049. doi: 10.3760/cma.j.issn.1001-9030.2018.08.049
[5]	Berbecka M, Forma A, Baj J, et al. A systematic review of the cyclooxygenase-2 (COX-2) expression in rectal cancer patients treated with preoperative radiotherapy or radiochemotherapy[J]. J Clin Med, 2021, 10(19): 4443. DOI: 10.3390/jcm10194443. doi: 10.3390/jcm10194443
[6]	Fumagalli A, Oost KC, Kester L, et al. Plasticity of Lgr5-negative cancer cells drives metastasis in colorectal cancer[J]. Cell Stem Cell, 2020, 26(4): 569-578. e7. DOI: 10.1016/j.stem.2020.02.008. doi: S1934-5909(20)30061-8 pmid: 32169167
[7]	刘英强, 陈淅涓, 韩广森, 等. 中低位局部进展期直肠癌新辅助同步放化疗前后G蛋白耦联受体蛋白的表达变化及其临床意义[J]. 中华实验外科杂志, 2019, 36(6): 1110-1113. DOI: 10.3760/cma.j.issn.1001-9030.2019.06.040. doi: 10.3760/cma.j.issn.1001-9030.2019.06.040
[8]	Morsy H, Gaballah A, Samir M, et al. LGR5, HES1 and ATOH1 in young rectal cancer patients in Egyptian[J]. Asian Pac J Cancer Prev, 2021, 22(9): 2819-2830. DOI: 10.31557/APJCP.2021.22.9.2819. doi: 10.31557/APJCP.2021.22.9.2819
[9]	Mirza-Aghazadeh-Attari M, Mohammadzadeh A, Yousefi B, et al. 53BP1: a key player of DNA damage response with critical functions in cancer[J]. DNA Repair (Amst), 2019, 73: 110-119. DOI: 10.1016/j.dnarep.2018.11.008. doi: 10.1016/j.dnarep.2018.11.008
[10]	Tang M, Feng X, Pei G, et al. FOXK1 participates in DNA damage response by controlling 53BP1 function[J]. Cell Rep, 2020, 32(6): 108018. DOI: 10.1016/j.celrep.2020.108018. doi: 10.1016/j.celrep.2020.108018
[11]	王燕, 张洛, 潘在用. P53蛋白表达与直肠癌术前同步放化疗敏感性研究[J]. 中华普通外科学文献(电子版), 2021, 15(2): 111-115. DOI: 10.3877/cma.j.issn.1674-0793.2021.02.007. doi: 10.3877/cma.j.issn.1674-0793.2021.02.007
[12]	Huang A, Xiao Y, Peng C, et al. 53BP1 expression and immunoscore are associated with the efficacy of neoadjuvant chemoradiotherapy for rectal cancer[J]. Strahlenther Onkol, 2020, 196(5): 465-473. DOI: 10.1007/s00066-019-01559-x. doi: 10.1007/s00066-019-01559-x pmid: 31828392
[13]	Tian G, Li G, Guan L, et al. Pretreatment albumin-to-alkaline phosphatase ratio as a prognostic indicator in solid cancers: a meta-analysis with trial sequential analysis[J]. Int J Surg, 2020, 81: 66-73. DOI: 10.1016/j.ijsu.2020.07.024. doi: S1743-9191(20)30559-8 pmid: 32745716
[14]	Li B, Deng H, Zhou Z, et al. The prognostic value of the fibrinogen to pre-albumin ratio in malignant tumors of the digestive system: a systematic review and meta-analysis[J]. Cancer Cell Int, 2022, 22(1): 22. DOI: 10.1186/s12935-022-02445-w. doi: 10.1186/s12935-022-02445-w pmid: 35033080
[15]	Lu S, Liu Z, Zhou X, et al. Preoperative fibrinogen-albumin ratio index (FARI) is a reliable prognosis and chemoradiotherapy sensitivity predictor in locally advanced rectal cancer patients under-going radical surgery following neoadjuvant chemoradiotherapy[J]. Cancer Manag Res, 2020, 12: 8555-8568. DOI: 10.2147/CMAR.S273065. doi: 10.2147/CMAR.S273065
[16]	Li H, Wang H, Shao S, et al. Pretreatment albumin-to-fibrinogen ratio independently predicts chemotherapy response and prognosis in patients with locally advanced rectal cancer undergoing total mesorectal excision after neoadjuvant chemoradiotherapy[J]. Onco Targets Ther, 2020, 13: 13121-13130. DOI: 10.2147/OTT.S288265. doi: 10.2147/OTT.S288265
[17]	Wang Y, Gao C, Zhou K, et al. MicroRNA-532-5p-programmed cell death protein 4 (PDCD4) axis regulates angiotensin Ⅱ-induced human umbilical vein endothelial cell apoptosis and proliferation[J]. Microvasc Res, 2021, 138: 104195. DOI: 10.1016/j.mvr.2021.104195. doi: 10.1016/j.mvr.2021.104195
[18]	Lai CY, Yeh KY, Liu BF, et al. MicroRNA-21 plays multiple oncometabolic roles in colitis-associated carcinoma and colorectal cancer via the PI3K/AKT, STAT3, and PDCD4/TNF-α signaling pathways in zebrafish[J]. Cancers (Basel), 2021, 13(21): 5565. DOI: 10.3390/cancers13215565. doi: 10.3390/cancers13215565
[19]	Dou X, Wang RB, Meng XJ, et al. PDCD4 as a predictor of sensitivity to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients[J]. Asian Pac J Cancer Prev, 2014, 15(2): 825-830. DOI: 10.7314/apjcp.2014.15.2.825. doi: 10.7314/apjcp.2014.15.2.825
[20]	Akiyoshi T, Gotoh O, Tanaka N, et al. T-cell complexity and density are associated with sensitivity to neoadjuvant chemoradiotherapy in patients with rectal cancer[J]. Cancer Immunol Immunother, 2021, 70(2): 509-518. DOI: 10.1007/s00262-020-02705-6. doi: 10.1007/s00262-020-02705-6
[21]	Chen TW, Huang KC, Chiang SF, et al. Prognostic relevance of programmed cell death-ligand 1 expression and CD8⁺ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy[J]. J Cancer Res Clin Oncol, 2019, 145(4): 1043-1053. DOI: 10.1007/s00432-019-02874-7. doi: 10.1007/s00432-019-02874-7
[22]	Rapoport BL, Anderson R. Realizing the clinical potential of immunogenic cell death in cancer chemotherapy and radiotherapy[J]. Int J Mol Sci, 2019, 20(4): 959. DOI: 10.3390/ijms20040959. doi: 10.3390/ijms20040959
[23]	Hack SP, Zhu AX, Wang Y. Augmenting anticancer immunity through combined targeting of angiogenic and PD-1/PD-L1 pathways: challenges and opportunities[J]. Front Immunol, 2020, 11: 598877. DOI: 10.3389/fimmu.2020.598877. doi: 10.3389/fimmu.2020.598877
[24]	Huang CY, Chiang SF, Ke TW, et al. Clinical significance of programmed death 1 ligand-1 (CD274/PD-L1) and intra-tumoral CD8⁺ T-cell infiltration in stage Ⅱ- Ⅲ colorectal cancer[J]. Sci Rep, 2018, 8(1): 15658. DOI: 10.1038/s41598-018-33927-5. doi: 10.1038/s41598-018-33927-5
[25]	Cui Y, Lyu X, Ding L, et al. Global miRNA dosage control of embryonic germ layer specification[J]. Nature, 2021, 593(7860): 602-606. DOI: 10.1038/s41586-021-03524-0. doi: 10.1038/s41586-021-03524-0
[26]	Ghafouri-Fard S, Esmaeili M, Taheri M. Expression of non-coding RNAs in hematological malignancies[J]. Eur J Pharmacol, 2020, 875: 172976. DOI: 10.1016/j.ejphar.2020.172976. doi: 10.1016/j.ejphar.2020.172976
[27]	Campayo M, Navarro A, Benítez JC, et al. miR-21, miR-99b and miR-375 combination as predictive response signature for preoperative chemoradiotherapy in rectal cancer[J]. PLoS One, 2018, 13(11): e0206542. DOI: 10.1371/journal.pone.0206542. doi: 10.1371/journal.pone.0206542
[28]	Machackova T, Trachtova K, Prochazka V, et al. Tumor microRNAs identified by small RNA sequencing as potential response predictors in locally advanced rectal cancer patients treated with neoadjuvant chemoradiotherapy[J]. Cancer Genomics Proteomics, 2020, 17(3): 249-257. DOI: 10.21873/cgp.20185. doi: 10.21873/cgp.20185
[29]	Kaneko K, Kawai K, Kazama S, et al. Clinical significance of mucinous components in rectal cancer after preoperative chemoradiotherapy[J]. Surg Today, 2017, 47(6): 697-704. DOI: 10.1007/s00595-016-1419-0. doi: 10.1007/s00595-016-1419-0 pmid: 27659290
[30]	Yao Y, Xu X, Yang L, et al. Patient-derived organoids predict chemoradiation responses of locally advanced rectal cancer[J]. Cell Stem Cell, 2020, 26(1): 17-26. e6. DOI: 10.1016/j.stem.2019.10.010. doi: S1934-5909(19)30431-X pmid: 31761724